The U.S. Food and Drug Administration has approved a daily oral version of the popular weight-loss drug Wegovy, marking a major milestone in obesity treatment. This first-of-its-kind GLP-1 weight-loss pill from Novo Nordisk contains the same active ingredient, semaglutide, found in the injectable Wegovy and Ozempic, and is expected to expand access to those who prefer a pill over injections.
Clinical trials showed significant weight reduction with average losses of roughly 14–17 % of body weight over about 15 months, results comparable to the injectable version. The pill must be taken once daily and is expected to hit the U.S. market soon.
This approval could broaden treatment options for millions of adults with obesity or overweight and related health conditions, offering a more convenient alternative to weekly injections and potentially driving wider adoption of effective weight-loss therapies.
Click here to read the entire article.
